ZUG, Switzerland, April 07, 2023 (GLOBE NEWSWIRE) -- Following the U.S. Food and Drug Administration’s decision, Covis Pharma Group (“Covis”) is effectuating the withdrawal of Makena® (hydroxyprogesterone caproate injection), which has been the only treatment approved to reduce the risk of preterm birth in pregnant women who have had a prior spontaneous preterm birth.
See the article here:
Covis Statement on FDA Decision to Withdraw Approval of Makena®
Recommendation and review posted by Fredricko
